期刊文献+

替加环素对4种耐药菌体外抗菌活性及其药效学评价 被引量:12

In vitro activities of tigecycline agaist four kinds of resistant bacteria and evaluate the pharmacodynamic of tigecycline
下载PDF
导出
摘要 目的测定替加环素对4种耐药菌的体外抗菌作用并对其药效学进行评价。方法采用微量肉汤稀释法测定替加环素对453株耐甲氧西林的金黄色葡萄球菌,421株泛耐药鲍曼不动杆菌,124株耐万古霉素的肠球菌以及235株产ESBLs的大肠埃希菌的最低抑菌浓度(MIC)。整理已发表的替加环素的药代动力学资料,设置AUC24/MIC>18对革兰阳性菌、AUC24/MIC>6.96对革兰阴性菌为替加环素的药效学目标,利用Crystal Ball软件模拟出5000例患者的目标获得概率并计算得出累积反应分数。结果替加环素对耐甲氧西林的金黄色葡萄球菌、耐万古霉素的肠球菌、产ESBLs的大肠埃希菌的敏感率为100%,对泛耐药鲍曼不动杆菌的敏感率仅为54.5%。蒙特卡罗模拟结果显示,对于耐甲氧西林的金黄色葡萄球菌、耐万古霉素的肠球菌、产ESBLs的大肠埃希菌,替加环素50mg剂量组的累积反应分数均达到90%以上。而替加环素50mg剂量组对泛耐药鲍曼不动杆菌的累积反应分数为13.34%,即使将药物剂量增加到100mg其累积反应分数也只有15.55%。结论除泛耐药的鲍曼不动杆菌外,替加环素对耐甲氧西林的金黄色葡萄球菌、耐万古霉素的肠球菌、产ESBLs的大肠埃希菌有很好的抗菌活性,临床上应用替加环素治疗泛耐药鲍曼不动杆菌可能无法达到理想的治疗效果。 Objective To determine the in vitro activity of tigecycline against four kinds of resistant bacteria and evaluate the pharmacodynamic of tigecycline. Methods The minimal inhibitory concentrations (MIC) of tigecycline against 453 strains of methicillin-resistant Staphylococcus aureus(MRSA), 421 strains of pan-drug resistant Acinetobacter baumannii(PDR-AB), 124 strains of vancomycin-resistant enterococci(VRE), and 235 strains of ESBL-producing E. coil were determined by the broth microdilution method. The population pharmacokinetic data of tigecycline reported previously were used to set up AUC24/MIC〉18 for Gram-positive and AUC24/MIC〉6.96 for Gram-negative as the pharmacodynamic targets. The PTA and CFR of 5000 patients were simulated using Crystal Ball software. Results The tigecycline susceptibility rates were 100% for MRSA, VRE, ESBL-producing E. coli and 54.5% for PDR-AB. Monte Carlo simulation results show that the CFR of tigecycline 50rag dose group for MRSA, VRE, ESBL-producing E. coli were more than 90% and 13.34% for PDR-AB, even increasing to 100mg doses the CFR for PDR-AB was 15.55%. Conclusion Except for PDR-AB, tigecycline is a novel broad spectrum antimicrobial that is active against MRSA, VRE and ESBL-producing E. coll. Clinically applied for treatment of PDR- AB may not be able to achieve ideal therapeutic effect.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2014年第4期311-315,共5页 Chinese Journal of Antibiotics
基金 国家自然科学基金资助项目(81071394)
关键词 替加环素 蒙特卡罗模拟 药动学 药效学 MIC Tigecycline Monte Carlo simulation Pharmacokinetic Pharmacodynamic MIC
  • 相关文献

参考文献16

  • 1Petersen P J, Jacobus N V, Weiss W J, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)[J]. Antimicrob Agents Chemother, 1999, 43(4): 738-744.
  • 2Mouton J W, Dudley M N, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update[J]. J Antimicrob Chemother, 2005, 55(5): 601-607.
  • 3Clinical and Laboratory Standard Intitute(CLSI) Performance standards for antimicrobial susceptibility testing; 19th informational supplement[M]. 2009, CLSI, MI00-S19.
  • 4Sader H S, Farrell D J, Jones R N. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005- 2009)[J]. Diagn Microbiol In feet Dism, 69(2): 223-227.
  • 5Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects[J]. Antimicrob Agents Chemother, 2005, 49(1): 220-229.
  • 6Ambrose P G, Meagher A K, Passarell J A, et al. Application of patient population-derived pharmacokinetic- pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococc[J]. Diagn Microbiol Infect Dis, 2009, 639(2): 155-159.
  • 7Passarell J A, Meagher A K, Liolios K, et al. Exposure- response analyses of tigecycline efficacy in patients with complicated intraabdominal infections[J]. Antimicrob Agents Chemother, 2008, 52(1): 204-210.
  • 8Silva S J, Reyna F F, Velazquez M M, et al. In vitro activity of tigecycline against extended-spectrum 13-lactamase- producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study[J]. Diagn Microbiol Infect Dis, 2011, 70(2): 270-273.
  • 9Dowzicky M J, Chmelarova E. Global in vitro activity of tigecycline and linezolidagainst Gram-positive organisms collected between 2004 and 2009[J]. lnt J Antimicrob Agents, 2011, 37(6): 562-566.
  • 10Chen Y H, Lu P L, Huang C H, et al. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the tigecycline in vitro surveillance in Taiwan Study, 2006 to 2010[J]. Antimierobial Agents Chemotherapy, 2011, 56(3): 1452-1457.

二级参考文献30

  • 1张婴元,张敬德,周乐,吴培澄,陈友娣,王宇倩,汪复.头孢哌酮-舒巴坦体外抗菌作用研究[J].中华内科杂志,1995,34(10):676-679. 被引量:52
  • 2石岩,刘大为,许大波,徐英春,陈民均,王辉.泛耐药鲍曼不动杆菌感染临床治疗初探[J].中国感染与化疗杂志,2007,7(1):34-37. 被引量:112
  • 3汪复.多重耐药铜绿假单胞菌与鲍曼不动杆菌严重感染的防治策略[J].中国感染与化疗杂志,2007,7(3):230-232. 被引量:138
  • 4RAEINA R, ESTENSSORO E, SAENZ G. , et al. Safe ant efficacy of colistin in acinetobacter and pseudomonas infections; a prospective cohort study [ J ]. In tensive Care Med, 2005,31 ( 8 ) : 1058.
  • 5HOLLOWAY K P, ROUPHAEL N G, WELLS J B, et al. Polymyxin B and doxyeycline ues in patients with multidrug-resistant Acinetobacter banmannii infections in the intensive care unit[J]. Ann Pharmacother, 2006,40 (14) : 1939-1945.
  • 6BAUER G, BERENS C, PROJAN S J, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethysulphate and drug-directed Fe^2+ cleavage of 16 rRNA[ J]. J Antimicrob Chemother, 2004,53(4) :592-599.
  • 7ZHANEL G G, HOMENUIK K, NICHOL K, et al. The glycylcyclines acomparative review with the tetracyclines [ J ]. Drugs, 2004,64 ( 1 ) : 63-88.
  • 8RICE L B. Challenges in identifying new antimicrobial agents effective for treating infection with Acinetobacter baumannii and Pseudomonas aeruginosa[J]. Clin Infect Dis ,2006,43 ( Suppl 2) :S100-S105.
  • 9Olson MW,Ruzin A,Feyfant E,et al.Functional,biophysical,and structural bases for antibacterial activity of tigecycline[J].Antimicrob Agents Chemother,2006,50(6):2156-2166.
  • 10Liu JW,Wang LS,Cheng YJ,et al.In-vitro activity of tigecy-cline against clinical isolates of Acinetobacter baumannii in tai-wan[J].Int J Antimicrob Agents,2008,32:S188-191.

共引文献47

同被引文献155

  • 1虞剑华.电烧伤及伤口特点[J].电力安全技术,2008,10(8):69-70. 被引量:1
  • 2Hai-Nv Gao, Wen-Xia Yuan, Mei-Fang Yang, Hong Zhao, Jian-Hua Hu, Xuan Zhang, Jun Fan, Wei-Hang Ma.Clinical signif icance of C-reactive protein values in antibiotic treatment for pyogenic liver abscess[J].World Journal of Gastroenterology,2010,16(38):4871-4875. 被引量:14
  • 3胡骁骅,张会英,葛艳玲,陈忠,覃凤均,蒋海燕,陈大福,孙永华.乌司他丁对严重烧伤后多脏器功能的保护作用[J].中华医学杂志,2005,85(41):2889-2894. 被引量:55
  • 4刘淑芳,张青山,王风秀.耐甲氧西林金黄色葡萄球菌感染治疗药物的选择[J].医药导报,2006,25(1):78-80. 被引量:15
  • 5American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [ J ]. Am J Respir Crit Care Med, 2005, 171 (4) : 388-416.
  • 6Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia [ J]. Diagn Mierobiol Infect Dis, 2010, 68 (2): 140-151.
  • 7Barbour A, Schmidt S, Ma B, et al. Clinical pharmacokinetics and pharmacodynamies of tigeeycline [ J ]. Clin Pharmacokinet, 2009, 48 (9): 575-584.
  • 8Cunha BA. Multidrug-resistant Gram-negative bacilli causing urinary tract infections clinical considerations [ J]. J Chemother, 2011,23 (3): 171-174.
  • 9Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital- acquired pneumonia [ J ]. Antimicrob Agents Chemother, 2013, 57 (4): 1756-1762.
  • 10File TM Jr. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines [ J]. Clin Infect Dis, 2010, 51 Suppl 1:S42-47.

引证文献12

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部